Latest News in the pharma Industry

Research & Development

AstraZeneca's first biologic respiratory medicine shows positive results in severe asthma

AstraZeneca's first biologic respiratory medicine shows positive results in severe asthma

8 Sep 2016

Benralizumab Phase III trials met primary and key secondary endpoints.

Read more 
Demand for Aquila BioMedica's specialist CRO services accelerates company expansion

Demand for Aquila BioMedica's specialist CRO services accelerates company expansion

7 Sep 2016

Company's immuno-oncology and histology services have allowed clients' go/no-go decisions to be made earlier in the drug development process and ultimately reduce clinical attrition.

Read more 
Non-drug device reduces COPD exacerbations - real-world study presented at ERS

Non-drug device reduces COPD exacerbations - real-world study presented at ERS

7 Sep 2016

The Aerobika device demonstrated a clinically-significant reduction in exacerbations in as little as 30 days of treatment, when used as an add-on to usual COPD medications.

Read more 
New findings confirm Ultibro Breezhaler consistently more effective than Seretide in reducing COPD flare-ups

New findings confirm Ultibro Breezhaler consistently more effective than Seretide in reducing COPD flare-ups

5 Sep 2016

Ultibro Breezhaler reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide in new analyses from FLAME study.

Read more 
New Data: Stiolto Respimat inhalation spray significantly improved exercise capacity in people with COPD

New Data: Stiolto Respimat inhalation spray significantly improved exercise capacity in people with COPD

5 Sep 2016

Tiotropium+olodaterol Respimat along with exercise training and behavior modification significantly increased exercise capacity compared to placebo.

Read more 
Merck pulls the plug on odanacatnib

Merck pulls the plug on odanacatnib

5 Sep 2016

Increased risk of stroke fails to support further development.

Read more 
Biogen’s investigational Alzheimer’s disease treatment aducanumab granted FDA Fast Track Designation

Biogen’s investigational Alzheimer’s disease treatment aducanumab granted FDA Fast Track Designation

2 Sep 2016

Company also provides update on new interim analysis from Phase Ib study.

Read more 
AirFluSal Forspiro showed superiority at 12 months over Seretide Diskus in persistence to treatment

AirFluSal Forspiro showed superiority at 12 months over Seretide Diskus in persistence to treatment

31 Aug 2016

New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide Diskus.

Read more 
Early results show aducanumab removes amyloid plaques in patients with Alzheimer's disease

Early results show aducanumab removes amyloid plaques in patients with Alzheimer's disease

31 Aug 2016

Results provide compelling support for the hypothesis that amyloid build-up is a key factor in driving cognitive decline in Alzheimer's disease.

Read more 
New Repatha analyses show efficacy and safety across risk groups

New Repatha analyses show efficacy and safety across risk groups

30 Aug 2016

Consistently reduced low-density lipoprotein cholesterol in patients across cardiovascular risk subgroups or with familial hypercholesterolemia.

Read more 
Cerecor announces initiation of second CERC-501 Phase II clinical trial in smokers

Cerecor announces initiation of second CERC-501 Phase II clinical trial in smokers

30 Aug 2016

Study to evaluate the effect of CERC-501 on stress-related smoking lapse.

Read more 
Elite announces development and license agreement with SunGen Pharma

Elite announces development and license agreement with SunGen Pharma

29 Aug 2016

Companies will collaborate to develop and commercialize four generic products - two CNS stimulants and two beta blockers.

Read more